Aclaris Therapeutics Q1 EPS $(0.24) Beats $(0.29) Estimate, Sales $2.40M Beat $1.37M Estimate
Aclaris Therapeutics Q1 EPS $(0.24) Beats $(0.29) Estimate, Sales $2.40M Beat $1.37M Estimate
Aclaris Therapeutics第一季度每股收益美元（0.24美元）超過預期（0.29美元），銷售額240萬美元超過137萬美元的預期
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.29) by 17.24 percent. This is a 42.86 percent increase over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $2.40 million which beat the analyst consensus estimate of $1.37 million by 75.04 percent. This is a 5.14 percent decrease over sales of $2.53 million the same period last year.
Aclaris Therapeutics（納斯達克股票代碼：ACRS）公佈的季度虧損爲每股0.24美元，比分析師普遍預期的0.29美元（0.29美元）高出17.24％。與去年同期每股虧損0.42美元（0.42）相比，增長了42.86％。該公司公佈的季度銷售額爲240萬美元，比分析師普遍預期的137萬美元高出75.04％。這比去年同期的253萬美元銷售額下降了5.14％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。